The in-vitro activity and beta-lactamase stability of carumonam

J Antimicrob Chemother. 1986 Jul;18(1):35-44. doi: 10.1093/jac/18.1.35.

Abstract

Carumonam is a monobactam with a beta-carbamyloxmethyl group at position 4. It inhibited 90% of Enterobacteriaceae at less than or equal to 8 mg/l and had in-vitro activity similar to that of cefotaxime, ceftazidime and aztreonam. Fifty per cent of Enterobacter, Citrobacter and Serratia isolates were inhibited by 4 mg/l, but isolates resistant to aztreonam and ceftazidime were not inhibited. Carumonam, like aztreonam, did not inhibit Gram-positive or anaerobic species. Carumonam was not destroyed by the common plasmid- and chromosomally-mediated beta-lactamases and was more stable than aztreonam to attack by the K-1 beta-lactamase of Klebsiella oxytoca. Carumonam inhibited Richmond-Sykes type Ia and Id beta-lactamases but was a poor inhibitor of type III enzymes. It did not induce beta-lactamases.

Publication types

  • Comparative Study

MeSH terms

  • Anti-Bacterial Agents / metabolism
  • Anti-Bacterial Agents / pharmacology*
  • Aztreonam / pharmacology
  • Cefotaxime / pharmacology
  • Ceftazidime / pharmacology
  • Culture Media
  • Gram-Negative Aerobic Bacteria / drug effects*
  • Microbial Sensitivity Tests
  • Piperacillin / pharmacology
  • Tobramycin / pharmacology
  • beta-Lactamase Inhibitors
  • beta-Lactamases / metabolism*

Substances

  • Anti-Bacterial Agents
  • Culture Media
  • beta-Lactamase Inhibitors
  • carumonam
  • Ceftazidime
  • beta-Lactamases
  • Aztreonam
  • Cefotaxime
  • Tobramycin
  • Piperacillin